Veille bibliographique COVID-19 et maladies du globule rouge

Partager sur :

L’équipe projet de la filière vous propose une veille bibliographique spécifique COVID-19 et maladies du globule rouge. Les articles proposés sont pour la plupart des « preprints » acceptés dans des journaux référencés dans PubMed. Ils sont classés par maladie, puis par date de publication.

Ces articles sont recensés à titre d’information et n’indiquent aucunement un cautionnement de leur contenu par la filière. La qualité et la pertinence de leur contenu et conclusions restent à l’appréciation des lecteurs. 

Dernière modification : 29 mai 2020.

Hémoglobinopathies – Pathologies associées du globule rouge

  • Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID-19 pandemic. Roy NB, Telfer P, Eleftheriou P, et al. Br J Haematol. [published online ahead of print, 2020 Apr 24]. doi: 10.1111/bjh.16687
  • Care of patients with hemoglobin disorders during the COVID-19 pandemic: an overview of recommendations. Taher AT, Bou-Fakhredin R, Kreidieh F, Motta I, De Franceschi L, Cappellini MD. Am J Hematol. [published online ahead of print, 2020 May 11]. doi: 10.1002/ajh.25857
  • Rare anaemias, sickle cell disease and COVID-19. Vives Corrons JL, De Sanctis V. Acta Biomed. 2020 May 11;91(2):216-217. doi: 10.23750/abm.v91i2.9532

Déficit en glucose-6-phosphate déshydrogénase (déficit en G6PD)

  • G6PD and chloroquine: Selecting the treatment against SARS-CoV-2? Kassi EN, Papavassiliou KA, Papavassiliou AG. J Cell Mol Med. [published online ahead of print, 2020 Apr 12]. doi: 10.1111/jcmm.15312
  • Is glucose-6-phosphate dehydrogenase enzyme deficiency a factor in Coronavirus-19 (COVID-19) infections and deaths? Aydemir D, Ulusu NN. Pathog Glob Health 2020 May;114(3):109-110. Epub 2020 Apr 14:1-2. doi: 10.1080/20477724.2020.1751388
  • G6PD deficiency in COVID-19 pandemic: “A ghost in the ghost”. Al-Abdi S, Al-Aamri M. Hematol Oncol Stem Cell Ther. [published online ahead of print, 2020 Apr 18]. doi: 10.1016/j.hemonc.2020.04.002
  • Acute hemolysis by hydroxychloroquine was observed in G6PD-deficient patient with severe COVID-19 related lung injury. De Franceschi L, Costa E, Dima F, Morandia M, Olivieri O. Eur J Intern Med. [published online ahead of print, 2020 Apr 20]. doi: 10.1016/j.ejim.2020.04.020
  • COVID‐19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose‐6‐phosphate dehydrogenase deficiency. Beauverd Y, Adam Y, Assouline B, Samii K. Eur J Haematol. [published online ahead of print, 2020 Apr 23]. doi: 10.1111/EJH.13432
  • The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene. Capoluongo ED, Amato F, Castaldo G. Clin Chem Lab Med. [published online ahead of print, 2020 Apr 24]. doi: 10.1515/cclm-2020-0442
  • G6PD deficiency‐associated hemolysis and methemoglobinemia in a COVID‐19 patient treated with chloroquine. Kuipers MT, van Zwieten R, Heijmans J, et al. Am J Hematol. [published online ahead of print, 2020 May 10]. doi: 10.1002/ajh.25862

Drépanocytose

  • COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Beerkens F, John M, Puliafito B, Corbett V, Edwards C, Tremblay D. Am J Hematol. [published online ahead of print, 2020 Apr 3]. doi: 10.1002/ajh.25809
  • Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Nur E, Gaartman AE, van Tuijn CFJ, Tang MW, Biemond BJ. Am J Hematol. [published online ahead of print, 2020 Apr 8]. doi: 10.1002/ajh.25821
  • Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. De Luna G, Habibi A, Deux JF, et al. Am J Hematol. [published online ahead of print, 2020 Apr 13]. doi: 10.1002/ajh.25833
  • Initiating adjunct low dose-hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic. DeBaun MR. Blood [published online ahead of print, 2020 Apr 13]. doi: 10.1182/blood.2020005992
  • COVID‐19 infection in patients with sickle cell disease. Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. Br J Haematol. [published online ahead of print, 2020 Apr 21]. doi: 10.1111/bjh.16734
  • Mitigating the effect of the COVID-19 pandemic on sickle cell disease services in African countries. Dexter D, Simons D, Kiyaga C, et al. Lancet Haematol. [published online ahead of print, 2020 Apr 23]. doi: 10.1016/S2352-3026(20)30122-8
  • Dramatic improvement after Tocilizumab of a severe COVID-19 in a child with sickle cell disease and acute chest syndrome. Odièvre MH, de Marcellus C, Ducou, et al. Am J Hematol. [published online ahead of print,  2020 May 1]. doi: 10.1002/ajh.25855
  • COVID-19 infection and sickle cell disease: a UK centre experience. McCloskey KA, Meenan J, Hall R, Tsitsikas DA. Br J Haematol. [published online ahead of print, 2020 May 5]. doi: 10.1111/bjh.16779
  • Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic. Nickel RS, Margulies S, Frazer B, Luban NLC, Webb J. Blood [published online ahead of print, 2020 May 13]. doi: 10.1182/blood.2020006582
  • Patients with sickle cell disease and suspected COVID‐19 in a pediatric ICU. Heilbronner C, Berteloot L, Tremolieres P, et al. Br J Haematol. [published online ahead of print, 2020 May 18]. doi: 10.1111/bjh.16802
  • Managing sickle cell patients with COVID-19 infection: the need to pool our collective experience. Sahu KK, Siddiqui AD, Cerny J. Br J Haematol. [published online ahead of print, 2020 May 23]. doi: 10.1111/bjh.16880
  • [Commentaire sur l’article DeBaun MR., Initiating adjunct low dose-hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic, mis en ligne le 13 avril et cité ci-dessus] COVID-19 and SCA: an old friend comes to the rescue. Novelli EM. Blood, 2020 May 28;135(22):1925-1926. doi: 10.1182/blood.2020006442

Thalassémie

  • Challenging times for children with transfusion-dependent thalassemia amid the COVID-19 pandemic. Yadav U, Pal R. Indian Pediatr. [published online ahead of print, 2020 Apr 7]. S097475591600155
  • SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience. Motta I, De Amicis MM, Pinto VM, et al. Am J Hematol. [published online ahead of print, 2020 Apr 20]. doi: 10.1002/ajh.25840
  • Implications of SARSr-CoV 2 infection in thalassemias: do patients fall into the « high clinical risk » category? Karimi M, De Sanctis V. Acta Biomed. 2020 May 11;91(2):50-56. doi: 10.23750/abm.v91i2.9592
  • The medical concerns of patients with thalassemias at the time of COVID-19 outbreak: the personal experience and the international recommendations. Canatan D, De Sanctis V. Acta Biomed. 2020 May 11;91(2):218-221. doi: 10.23750/abm.v91i2.9533